Previous close | 2.1200 |
Open | 2.3850 |
Bid | 2.3600 x 1500 |
Ask | 2.3900 x 1600 |
Day's range | 2.1300 - 2.5254 |
52-week range | 0.7000 - 3.4000 |
Volume | |
Avg. volume | 6,782,540 |
Market cap | 448.88M |
Beta (5Y monthly) | 0.82 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Significant Growth and FDA Approvals Propel Performance
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 525% and 159.32%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.